Synairgen reports positive safety data for SNG001 in phase 2 COPD trial
SNG001 was shown to be well tolerated in the two-part mid-stage trial, dubbed SG015, as per the interim safety data, said the UK-based respiratory drug discovery and development
China’s National Medical Products Administration (NMPA) has granted marketing authorisation for Bio-Thera Solutions’ BAT2506 to treat ankylosing spondylitis and rheumatoid arthritis.
Persistent GERD affects an estimated 10 million Americans who continue to suffer from heartburn and regurgitation despite receiving treatment with proton pump inhibitors (PPIs), the current standard of
Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug